Life After 1st Line Targeted Therapy: What Next?

Submitted by dr. weiss on Wed, 10/08/2014 - 06:00

Jared Weiss, MD, Faculty and Board Vice President

Dr. Jared Weiss of the University of North Carolina addressed the Acquired Resistance in Lung Cancer Patient Forum with information on what patients' options are when their ALK, ROS1 or EGFR lung cancer progresses.

Related Content: 
Chemotherapy Selection for 1st line Non-Small-Cell Lung Cancer (NSCLC) — The Importance of Getting it Right the First Time

 

Join the Conversation

Please feel free to offer comments and raise questions in our
discussion forums.

 Join The conversation